AUXL: Auxilium Pharmaceuticals, Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, June 14, 1:28 PM Auxilium Pharmaceuticals (AUXL +2.3%) moves up after analysts at Mizuho initiate coverage with a Buy rating and a $28 price target. Comment! [Healthcare, On the Move]
Wednesday, June 5, 7:50 AM Auxilium Pharmaceuticals (AUXL) gets an upgrade to Outperform from Market Perform at Leerink Swann (price target to $21 from $16). Like SA contributor PropThink, analyst Joseph Schwartz has a rosy outlook for EPS accretion related to the Actient acquisition (Jefferies sees FY13 and FY14 non-GAAP EPS of $0.49 and $1.34) and says he is "optimistic for FDA approval of Xiaflex in Peyronie's disease (previous) in a few months." (Also: Stifel upgrades AUXL) Comment! [Healthcare]
Tuesday, April 30, 11:48 AM Shares of Auxilium Pharmaceuticals (AUXL +3.5%) appear to have leveled out after yesterday's earnings-related drubbing, inching higher this morning after Stifel Nicolas upgraded the shares to Buy with a $19 price tag on the weakness. Comment! [Healthcare, On the Move, Earnings]
Monday, April 29, 3:17 PM Shares of Auxilium Pharmaceuticals (AUXL -12.8%) take a big hit today on a disappointing Q1 report, missing on both EPS and revenue. The company cites some some "unanticipated challenges" with its commercial franchises for the miss. For FY13, its expects revenues of $360M - $415M, which reflects the closing of the acquisition of Actient, and may not be comparable to consensus estimates of $334.34M. 1 Comment [Earnings, Healthcare, On the Move]
Monday, April 29, 12:56 PM Midday top 10 gainers: OSH +43%. WRLS +31%. CPTS + 19%. MDSO +20%. GALT +19%. LEDS +18%. FXEN +17%. OSBC +14%. PRGN +12%. CCH +12%.
Midday top 10 losers: LAS -31%. NTE -28%. HGSH -20%. GWAY -19%. LXRX -18%. FVE -15%. AUXL -11%. MLP -10%. CETV -10%. BIOL -10%. Comment! [On the Move]
Monday, April 29, 7:02 AM Auxilium Pharmaceuticals (AUXL): Q1 EPS of -$0.05 misses by $0.11. Revenue of $66.2M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 29, 12:05 AM Notable earnings before Monday’s open: AUDC, AUXL, BWP, CMP, CYOU, EDR, ETN, FVE, L, MCY, ROP, SNH, SOHU, TEN Comment! [Earnings]
Sunday, April 28, 5:30 PM Notable earnings before Monday’s open: AUDC, AUXL, BWP, CMP, CYOU, EDR, ETN, FVE, L, MCY, ROP, SNH, SOHU, TEN Comment! [Earnings]
Monday, March 25, 3:28 PM Auxilium Pharmaceuticals (AUXL +3%) trades higher today after reporting positive top-line data from Phase II studies of its investigational treatment, Xiaflex, for adhesive capsulitis or Frozen Shoulder syndrome. The company said that the trial achieved statistically significant improvement in active forward flexion in the affected shoulder of patients compared to those who were only instructed to perform home shoulder exercises, its primary endpoint. It expects to commence the next phase trials for in H213. Comment! [Healthcare, On the Move]
Tuesday, February 26, 9:10 AM Premarket gainers: CWH +28%. ALC +22%. ARWR +17%. AXTI +8%. SPRD +7%. AUXL +6%. DCTH +5%.
Losers: TWI -10%. VVUS -7%. VSI -7%. EEQ -5%. 1 Comment [On the Move]
Tuesday, February 26, 7:10 AM Auxilium Pharmaceuticals (AUXL): Q4 EPS of $1.83 beats by $0.12. Revenue of $172.5M beats by $1.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 26, 12:05 AM Notable earnings before Tuesday’s open: AG, AKRX, AMED, AMT, AUXL, AZO, BMO, BYD, CBRL, CIE, CMLP, CRZO, ECL, EXPD, GTI, HD, HFC, M,MFA, PCS, RRD, RSH, SKS, SPRD, SRE, THC, TSL, UNFI, UTHR Comment! [Earnings]
Monday, February 25, 5:30 PM Notable earnings before Tuesday’s open: AG, AKRX, AMED, AMT, AUXL, AZO, BMO, BYD, CBRL, CIE, CMLP, CRZO, ECL, EXPD, GTI, HD, HFC, M,MFA, PCS, RRD, RSH, SKS, SPRD, SRE, THC, TSL, UNFI, UTHR Comment! [Earnings]
Tuesday, February 5, 11:29 AM Auxilium Pharmaceuticals (AUXL +0.3%) and strategic partner BioSpecifics (BSTC +1.3%) both move up after The Journal of Urology publishes its Impress Study, a Phase 3 trial of Xiaflex for the treatment of Peyronie's disease, which is an excess of inelastic collagen causing penile curvature deformity. AUXL previously announced positive top-line efficacy and safety results of the studies' co-primary endpoints, and based on the new results, has submitted a supplemental Biologics License Application (sBLA) to the FDA. Comment! [Healthcare, On the Move]
Thursday, January 31, 2:17 PM Auxilium (AUXL +4.6%) trades up today after it closes on a $350M offering of 150% convertible senior notes maturing in 2018, including $25.0 million of notes issued to underwriters to cover overallotments. The company intends to use the proceeds to fund potential acquisitions, as well as for general corporate purposes. Comment! [Healthcare, On the Move]
Thursday, January 24, 2:48 PM Auxilium Pharmaceuticals (AUXL -2%) slips today after saying its planning a $200M offering of convertible senior notes due 2018. Comment! [Healthcare, On the Move]

AUXL Auxilium Pharmaceuticals, Inc.

AUXL

Auxilium Pharmaceuticals, Inc.